Value of radiotherapy in metastatic HER2-overexpressing breast cancer treated with pyrotinib
10.3760/cma.j.cn112271-20240412-00131
- VernacularTitle:放射治疗在吡咯替尼治疗转移性HER2过表达乳腺癌中的价值
- Author:
Nan SUN
1
;
Xianglu SUN
;
Jing LIU
;
Yan YANG
;
Yongchun ZHOU
Author Information
1. 蚌埠医科大学第一附属医院肿瘤放疗科，蚌埠 233000
- Publication Type:Journal Article
- Keywords:
Metastatic breast cancer;
Human epidermal growth factor receptor 2;
Radiotherapy;
Pyrotinib
- From:
Chinese Journal of Radiological Medicine and Protection
2025;45(3):183-187
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of radiotherapy in postoperative metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treated with pyrotinib, and to identify potential subgroups that may benefit from this strategy.Methods:The clinical data of 187 patients with postoperative distant metastatic HER2-overexpressing breast cancer who received pyrotinib at the First Affiliated Hospital of Bengbu Medical University from January 2018 to July 2022 were retrospectively analyzed. The Kaplan-Meier method was used to assess changes in survival outcomes in patients undergoing radiotherapy. Univariate and multivariate analyses were conducted to identify prognostic factors, and the log-rank test was used to determine potential subgroups that may benefit from radiotherapy.Results:Among the 187 patients, 76 received radiotherapy. The median follow-up duration for the entire population was 16.9 months (range: 3.1-37.9 months), and the 2-year overall survival (OS) was 75.0%. Multivariate analysis showed that age, metastatic status, and radiotherapy were independent factors affecting OS (3.86-6.76, P<0.05). Further subgroup analysis showed that radiotherapy significantly improved OS in patients aged ≥50 years, those with oligometastases or bone metastases, those not receiving endocrine therapy, and those resistant to trastuzumab ( P<0.05). Conclusions:Radiotherapy, in addition to pyrotinib, can enhance the survival rate of patients with postoperative metastatic HER2-overexpressing breast cancer. The benefits of radiotherapy may be more pronounced in patients with a low tumor burden, inadequate systemic treatment, and drug resistance.
